Medroxyprogesterone Acetate (Provera) - Comprehensive Research Paper

1. Summary

Medroxyprogesterone acetate (MPA), marketed as Provera (oral) and Depo-Provera (injectable), is a synthetic progestin FDA-approved since 1959 for multiple indications including endometrial protection in hormone replacement therapy (HRT), secondary amenorrhea, abnormal uterine bleeding, and contraception. MPA was granted FDA approval on 18 June 1959, initially under the brand name Provera for treating amenorrhea and other conditions. In 1992, the medication was finally approved by the FDA, under the brand name Depo-Provera, for use in contraception.

Chemical Structure: MPA has the chemical formula C24H34O4. MPA is a 17-acetoxyprogesterone compound. Unlike most synthetic progestins derived from testosterone analogs, MPA is structurally most closely related to progesterone itself, though it differs in its pharmacological profile and receptor activity.

HRT Role: In postmenopausal women with an intact uterus receiving estrogen therapy, MPA is co-administered to prevent endometrial hyperplasia and reduce the risk of endometrial cancer. Estrogen administration unopposed by progestin has been associated with an increased risk of endometrial hyperplasia, which may be a precursor to cancer. Standard HRT regimens include continuous combined (2.5 mg MPA daily) or cyclic (10 mg MPA for 10-14 days per month).

Women's Health Initiative (WHI) Study Findings: The WHI estrogen plus progestin substudy, which tested conjugated equine estrogens (CEE) 0.625 mg combined with MPA 2.5 mg, was stopped early after 5.6 years due to increased risks of:

• 7 more coronary heart disease (CHD) events per 10,000 women-years
• 8 more strokes per 10,000 women-years
• 10 more pulmonary emboli (PE) per 10,000 women-years
• 8 more invasive breast cancers per 10,000 women-years

Critical Comparative Insight: Since the CEE-alone arm showed no increase in breast cancer, investigators speculated that continuous use of MPA may have played a role in the increased breast cancer risk. This observation has led to increased clinical interest in bioidentical micronized progesterone as an alternative to synthetic progestins for endometrial protection.

Breast Cancer Risk Comparison - Meta-Analysis: Based on meta-analysis of cohort studies, progesterone was found to be associated with lower breast cancer risk compared to synthetic progestins in combination with estrogen (RR = 0.67, 95% CI 0.55–0.81). This represents approximately a 33% lower breast cancer risk with bioidentical progesterone compared to synthetic progestins like MPA.

Mechanistic Breast Tissue Studies: Breast biopsy studies have shown that MPA significantly increased proliferation markers (Ki-67) and growth factor gene expression, while micronized progesterone did not. This differential effect on breast tissue proliferation may explain the divergent breast cancer risk profiles.

Clinical Positioning: Despite safety concerns highlighted by the WHI study, MPA remains widely prescribed due to its low cost, extensive clinical experience, and proven efficacy for endometrial protection. Generic MPA is available at costs as low as $2.92-$24.64 for 10 tablets (10 mg) with coupons, making it significantly more affordable than branded progesterone products. However, prescribers increasingly consider bioidentical alternatives for women at elevated breast cancer risk or with significant side effects from MPA.

Formulations and Routes:

• Oral tablets: 2.5 mg, 5 mg, 10 mg for HRT, amenorrhea, abnormal uterine bleeding
• Intramuscular injection (Depo-Provera): 150 mg/mL administered every 3 months for contraception
• Subcutaneous injection (Depo-SubQ Provera 104): 104 mg/0.65 mL administered every 3 months for contraception and endometriosis

November 2025 FDA Black Box Warning Update: In November 2025, the FDA removed the black box warning for cardiovascular disease, breast cancer, and dementia from menopausal hormone therapy products. However, the warning for endometrial cancer with unopposed estrogen was retained, reinforcing the necessity of progestogen co-administration (like MPA) in women with intact uteri receiving systemic estrogen.

Clinical Considerations:

• MPA provides effective endometrial protection but carries higher breast cancer risk than bioidentical progesterone
• Common side effects include weight gain, mood changes, depression, and fluid retention
• Contraindicated in active thromboembolism, pregnancy, undiagnosed vaginal bleeding, and known/suspected breast cancer
• Generic availability offers substantial cost savings (90-95% reduction vs. branded Provera)
• CYP3A4 substrate: drug interactions with rifampin, carbamazepine, St. John's wort reduce efficacy

2. FDA Approval Status and Indications

FDA Approval History

Oral Medroxyprogesterone Acetate (Provera): Medroxyprogesterone acetate was granted FDA approval on 18 June 1959, initially under the brand name Provera. The initial approved indications were secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology.

Injectable Formulation (Depo-Provera): In 1992, the medication was finally approved by the FDA, under the brand name Depo-Provera, for use in contraception. The intramuscular formulation (150 mg/mL) provides 3 months of contraceptive protection with a single injection.

Subcutaneous Formulation (Depo-SubQ Provera 104): On 22 December 2004, medroxyprogesterone acetate was granted FDA approval for the subcutaneous formulation Depo-SubQ Provera 104. This formulation delivers 104 mg in 0.65 mL and is approved for contraception and management of endometriosis-associated pain.

FDA-Approved Indications

Oral Medroxyprogesterone Acetate (Provera Tablets):

1. Secondary Amenorrhea: Provera tablets are indicated for secondary amenorrhea. MPA is used to induce withdrawal bleeding in women with absent menses due to hormonal imbalance (not pregnancy or anatomical abnormalities).

2. Abnormal Uterine Bleeding: Provera tablets are indicated for abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.

3. Endometrial Hyperplasia Prevention: Provera tablets are indicated for use in non-pregnant women to reduce the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving daily oral conjugated estrogens 0.625 mg.

   Critical Rationale: Estrogen administration unopposed by progestin has been associated with an increased risk of endometrial hyperplasia, which may be a precursor to cancer. The addition of a progestin for 10 or more days of a cycle of estrogen administration has been shown to reduce the incidence of endometrial hyperplasia significantly.

Injectable Medroxyprogesterone Acetate (Depo-Provera, Depo-SubQ Provera 104):

1. Contraception: Depo-Provera Contraceptive Injection and Depo-SubQ Provera 104 are indicated for the prevention of pregnancy in women of childbearing potential.

2. Endometriosis-Associated Pain (Depo-SubQ Provera 104 only): Depo-SubQ Provera 104 is indicated for management of endometriosis-associated pain.

Off-Label Uses

While not FDA-approved for these indications, MPA is used off-label for:

• Hormone therapy in transgender men: Suppression of menses
• Hyperandrogenism/PCOS: Menstrual regulation and endometrial protection
• Precocious puberty: Suppression of premature sexual development

Goal Relevance:

• I want to manage my irregular menstrual cycles and reduce abnormal uterine bleeding.
• I'm looking for a reliable contraceptive method that I only need to think about every few months.
• I need to protect my uterus while undergoing hormone replacement therapy during menopause.
• I want to prevent endometrial cancer while taking estrogen therapy.
• I'm seeking a cost-effective hormone therapy option for managing menopausal symptoms.
• I need help with managing secondary amenorrhea and restoring my menstrual cycle.
• I'm concerned about the risk of breast cancer with hormone therapy and want to explore safer alternatives.

Goal Archetype Integration

Synthetic Progestin Classification

Medroxyprogesterone acetate (MPA) is a synthetic progestin (also called a progestogen or progestational agent), NOT bioidentical progesterone. This distinction is clinically critical:

Structural Differences from Bioidentical Progesterone:

Why This Matters for Goal Archetypes:

1. "I want to protect my breast health while managing menopause" - MPA is NOT the optimal choice. Meta-analysis shows 33% higher breast cancer risk vs micronized progesterone (RR 0.67 for progesterone vs progestins).

2. "I need the most affordable HRT option" - MPA may be appropriate. Generic MPA ($3-15/month) is comparable to generic micronized progesterone ($3-33/month), but MPA is more widely available.

3. "I want bioidentical hormones only" - MPA does NOT fulfill this goal. It is synthetic by definition and should be replaced with micronized progesterone (Prometrium or compounded).

4. "I'm primarily concerned about preventing endometrial cancer" - MPA effectively fulfills this goal. PEPI trial showed equivalent endometrial protection (1-2% hyperplasia rate) for both MPA and micronized progesterone.

WHI Study Risk Profile - Goal-Oriented Analysis

The Women's Health Initiative (WHI) findings must be contextualized within patient goal archetypes:

Absolute Risks per 10,000 Women-Years (CEE 0.625mg + MPA 2.5mg):

Risk-Benefit by Goal Archetype:

High-Priority Goals Where MPA May Be Acceptable:

• Endometrial protection (primary indication)
• Cost containment (generic widely available)
• Predictable bleeding control (continuous combined regimen)
• Bone protection (fracture reduction documented)

High-Priority Goals Where MPA Should Be Avoided:

• Breast cancer risk minimization (use micronized P4)
• Cardiovascular protection (consider transdermal E2 + micronized P4)
• Mood stability (MPA has higher depression incidence)
• Weight management (MPA associated with greater weight gain)

Archetype-Specific Recommendations

Archetype 1: "The Cautious Optimizer" Profile: Wants effective HRT with lowest possible risk

• MPA Recommendation: NOT first-line
• Rationale: 33% higher breast cancer risk vs micronized P4 unacceptable for risk-averse patients
• Alternative: Micronized progesterone 100-200mg cyclic or continuous

Archetype 2: "The Budget-Conscious Patient" Profile: Needs effective HRT at minimal cost

• MPA Recommendation: ACCEPTABLE option
• Rationale: Generic MPA $3-15/month provides equivalent endometrial protection
• Counseling: Discuss breast cancer risk differential; document informed consent

Archetype 3: "The Symptom-Focused Patient" Profile: Prioritizes vasomotor symptom relief above other concerns

• MPA Recommendation: ACCEPTABLE as progestogen component
• Rationale: Equivalent efficacy for endometrial protection; estrogen drives symptom relief
• Alternative consideration: If mood symptoms emerge, switch to micronized P4

Archetype 4: "The Breast Cancer-Concerned Patient" Profile: Strong family history or elevated Gail score

• MPA Recommendation: CONTRAINDICATED relative
• Rationale: WHI showed breast cancer increase only with CEE+MPA, not CEE alone
• Mandatory alternative: Micronized progesterone or levonorgestrel IUD

Age-Stratified Dosing

Dosing by Age and Menopausal Status

Premenopausal Women (Ages 18-44)

Perimenopausal Women (Ages 45-55, Still Cycling)

Early Postmenopausal Women (Ages 50-59, Within 10 Years of LMP)

Late Postmenopausal Women (Ages 60-69, >10 Years Post-LMP)

Elderly Women (Ages 70+)

Age-Specific Dosing Rationale

The Timing Hypothesis

WHI subgroup analyses revealed that cardiovascular risk varies dramatically by age at HRT initiation:

Clinical Implication: MPA (as part of combined HRT) should be initiated within 10 years of menopause onset for optimal benefit-risk profile. The November 2025 FDA guidance codifies this timing-based approach.

Adolescent Considerations (Depo-Provera Contraception)

Bone Mineral Density Concerns: Depo-Provera causes 5-7% BMD loss at lumbar spine in first 2 years. Adolescents are accruing peak bone mass during this period.

Premature Ovarian Insufficiency (POI) - Age <40

Women with POI require HRT until natural menopause age (~51) regardless of chronological age:

Drug Interactions - Expanded Analysis

CYP3A4 Interactions - Quantitative Impact

MPA is metabolized primarily by CYP3A4. Drug interactions can significantly alter plasma concentrations:

CYP3A4 Inducers (DECREASE MPA Levels) - Clinical Management:

CYP3A4 Inhibitors (INCREASE MPA Levels) - Clinical Management:

Hormone Interactions

Estrogen Interactions:

Thyroid Hormone:

Insulin and Oral Hypoglycemics:

Anticoagulant Interactions

Psychiatric Medication Interactions

Herbal and Supplement Interactions

Bloodwork Impact

Hormonal Panel Effects

Progesterone Levels:

Estrogen Levels:

Gonadotropins (FSH, LH):

Lipid Panel Effects

MPA has documented effects on lipid parameters that differ from micronized progesterone:

PEPI Trial Lipid Findings: The PEPI trial demonstrated that CEE alone increased HDL-C by 5.6 mg/dL, but CEE + MPA continuous blunted this increase to 1.6 mg/dL (70% reduction in HDL benefit). This attenuation of estrogen's HDL benefit may contribute to the cardiovascular risk difference observed in WHI.

Glucose and Metabolic Panel

Coagulation Parameters

Clinical Implication: Routine coagulation screening is NOT recommended before HRT initiation in women without personal/family VTE history. However, these changes explain the mechanistic basis for increased VTE risk.

Liver Function Tests

Hepatic Contraindication: MPA is contraindicated in active liver disease. Baseline LFTs recommended; discontinue if significant elevation occurs.

Thyroid Function Tests

Bone Turnover Markers (Injectable MPA/Depo-Provera)

Clinical Implication: Bone turnover markers are not routinely recommended for Depo-Provera monitoring. BMD (DXA scan) is the appropriate test if bone health assessment is needed after prolonged use (>2 years).

Recommended Bloodwork Schedule

Baseline (Before MPA Initiation):

• Complete metabolic panel (glucose, renal, liver function)
• Lipid panel
• TSH
• Consider: CBC, coagulation studies (only if VTE risk factors)

3-Month Follow-Up:

• No routine labs required
• Consider lipid panel if baseline dyslipidemia

Annual Monitoring:

• Fasting glucose or HbA1c (especially in metabolic syndrome/diabetes)
• Lipid panel
• TSH (only if on levothyroxine or thyroid symptoms)
• LFTs (only if baseline abnormal or hepatic symptoms)

Protocol Integration

Historical Context: Why MPA Dominated HRT

Pre-WHI Era (1959-2002):

MPA became the dominant progestogen in US HRT for several reasons:

1. First-mover advantage: FDA approval in 1959 established MPA as the standard progestogen before alternatives existed.

2. Pharmaceutical development: Pfizer (Provera) and later Wyeth (Prempro = Premarin + MPA) invested heavily in clinical trials and marketing.

3. PEPI Trial validation (1995): Demonstrated MPA's efficacy for endometrial protection, cementing its role in combined HRT.

4. Regulatory pathway: Combined CEE + MPA products (Prempro, Premphase) offered prescribing convenience and had established FDA approval.

5. Cost and availability: Generic MPA was inexpensive and universally available.

Post-WHI Era (2002-Present):

The WHI study (published 2002) fundamentally changed the HRT landscape:

1. Dramatic HRT decline: US HRT prescriptions dropped 50-70% within 2 years of WHI publication.

2. MPA scrutiny: Recognition that CEE-alone arm showed no breast cancer increase focused attention on MPA's specific contribution.

3. Bioidentical movement: Patient demand for "natural" hormones drove interest in micronized progesterone.

4. French E3N data: Large cohort study showing lower breast cancer risk with progesterone vs synthetic progestins (2005-2008 publications).

5. Meta-analysis confirmation (2016): RR 0.67 for breast cancer with progesterone vs progestins provided definitive evidence.

Why Micronized Progesterone is Now Preferred

Evidence-Based Rationale:

Clinical Guideline Evolution:

The 2022 North American Menopause Society (NAMS) position statement and 2023 Endocrine Society guidelines now acknowledge:

• Micronized progesterone may be preferred over MPA due to breast safety profile
• Transdermal estradiol + oral micronized progesterone may have lower VTE risk than oral CEE + MPA
• Patient preference for bioidentical hormones is a valid consideration

When MPA Remains Appropriate

Despite the preference for micronized progesterone, MPA remains clinically appropriate in specific situations:

1. Adherence Concerns:

• Micronized progesterone causes sedation in 20-30% of users, requiring bedtime dosing
• MPA can be taken any time of day without sedation
• Women who cannot maintain bedtime medication routine may do better with MPA

2. Daytime Progestogen Requirement:

• Some women need to take all medications in the morning
• MPA's lack of sedation allows flexible dosing

3. Historical Good Tolerance:

• Women who have used MPA for years without side effects may continue
• "If it ain't broke, don't fix it" applies

4. Micronized Progesterone Intolerance:

• Some women experience excessive sedation or dizziness with micronized progesterone
• MPA is a reasonable second-line option

5. Peanut Allergy (Prometrium):

• Prometrium capsules contain peanut oil
• MPA is an alternative for women with peanut allergy
• (Note: Compounded micronized progesterone without peanut oil is also available)

Protocol Transition: MPA to Micronized Progesterone

For patients currently on MPA who wish to transition to micronized progesterone:

Step 1: Confirm Appropriateness

• Review breast cancer risk factors
• Assess current side effects (mood, weight)
• Confirm no peanut allergy (if using Prometrium)

Step 2: Dose Equivalence

Step 3: Transition Protocol

• Option A: Direct switch at equivalent dose
• Option B: Overlap by 1 week (take both, then discontinue MPA)

Step 4: Counseling

• Expect sedation with micronized progesterone; take at bedtime
• Bleeding patterns may change temporarily
• Follow-up in 3 months to assess tolerance

Step 5: Monitoring

• Lipid panel at 3-6 months (expect HDL improvement)
• Mood assessment (expect improvement if mood issues with MPA)
• Weight monitoring (expect stabilization or mild loss)

Protocol-Specific Dosing Integration

Combined Oral HRT Protocol:

Cyclic/Sequential Protocol:

Transdermal Estrogen + Oral Progestogen Protocol:

Intrauterine Progestogen Protocol:

Integration with DosingIQ Archetypes

Longevity-Focused Protocol:

• Preferred: Transdermal E2 + Micronized P4
• MPA role: NOT recommended (breast cancer, CV concerns)
• Alternative: Transdermal E2 + LNG-IUD

Symptom-Focused Protocol:

• Preferred: Oral E2 + Micronized P4 (sedation may help sleep)
• MPA role: Acceptable if P4 intolerance
• Monitoring: Mood, weight, breakthrough bleeding

Bone-Focused Protocol:

• Preferred: Any HRT regimen (E2 + P4 or E2 + MPA)
• MPA role: Equivalent bone protection to P4
• Consideration: If Depo-Provera for contraception, monitor BMD

Fertility Transition Protocol (Perimenopause):

• Preferred: Cyclic E2 + Cyclic P4 (mimics natural cycle)
• MPA role: Acceptable for cycle regulation
• Note: Neither MPA nor P4 at HRT doses provides contraception

3. Mechanism of Action

Chemical Structure

MPA has the chemical formula C24H34O4. MPA is a 17-acetoxyprogesterone compound. The chemical structure consists of progesterone with:

• Acetoxy group at C17: Enhances oral bioavailability and extends half-life
• 6α-methyl group: Increases progestational potency and receptor affinity

Structural Distinction from Other Progestins: Unlike most other synthetic progestins, MPA is structurally most closely related to progesterone, instead of testosterone, and possesses less androgenic activity compared to 19-nortestosterone derivatives (e.g., norethindrone, levonorgestrel).

Receptor Binding and Activity

Progesterone Receptor Agonism: While both MPA and its deacetylated analogue medroxyprogesterone bind to and agonize the PR, MPA has approximately 100-fold higher binding affinity and transactivation potency in comparison. This increased potency explains MPA's effectiveness at lower doses compared to natural progesterone.

Multi-Receptor Activity: MPA also acts as an agonist of the androgen receptor (AR) and the glucocorticoid receptor (GR), though with lower affinity. This multi-receptor activity contributes to both therapeutic effects and side effects:

• AR agonism: May contribute to acne, hirsutism, and weight gain in some women
• GR agonism: May contribute to bone density effects, mood changes, and metabolic effects

Endometrial Effects

Secretory Transformation: Medroxyprogesterone acetate transforms proliferative endometrium into secretory endometrium. This transformation is the basis for MPA's therapeutic effects in:

• Secondary amenorrhea: Withdrawal bleeding after MPA administration indicates adequate estrogen priming and functional endometrium
• Endometrial protection: Opposing estrogen-induced proliferation reduces hyperplasia risk

Cellular Mechanisms: Progesterone receptor activation in endometrial epithelial cells leads to:

1. Downregulation of estrogen receptors: Reduces estrogen-driven proliferation
2. Induction of 17β-hydroxysteroid dehydrogenase type 2: Converts estradiol to less potent estrone
3. Suppression of mitotic activity: Reduces cell division and endometrial thickness
4. Stromal decidualization: Differentiates stromal cells into decidual cells

Contraceptive Mechanisms (Injectable Formulations)

Ovulation Inhibition: Depo-Provera Contraceptive Injection inhibits the secretion of gonadotropins which prevents follicular maturation and ovulation. This is the primary contraceptive mechanism.

Additional Contraceptive Effects:

• Cervical mucus thickening: Impairs sperm penetration
• Endometrial atrophy: Creates inhospitable environment for implantation

Breast Tissue Effects - Critical Mechanistic Concern

Proliferation Marker Studies: Breast biopsy studies comparing estrogen plus MPA versus estrogen plus micronized progesterone showed that MPA significantly increased proliferation markers (Ki-67) and growth factor gene expression, while micronized progesterone did not.

Quantitative Proliferation Data: Studies measuring Ki-67 (a marker of cellular proliferation) in breast tissue biopsies found:

• Estrogen + MPA: Significant increase in Ki-67-positive cells (indicating increased proliferation)
• Estrogen + micronized progesterone: No significant increase in Ki-67-positive cells
• Estrogen alone: Increase in Ki-67, but less than estrogen + MPA

Clinical Implication: This differential effect on breast tissue proliferation provides a mechanistic explanation for why the WHI study found increased breast cancer risk with CEE + MPA but not with CEE alone.

4. Dosing Guidelines

Hormone Replacement Therapy (HRT) - Endometrial Protection

Continuous Combined Regimen: The recommended dose of medroxyprogesterone acetate in combination with estrogen therapy is 2.5 mg daily.

Regimen Details:

• Estrogen dose: Conjugated estrogens 0.625 mg daily
• MPA dose: 2.5 mg daily
• Schedule: Both medications taken continuously without interruption
• Rationale: Provides consistent endometrial protection and eliminates withdrawal bleeding after initial adjustment period

Cyclic/Sequential Regimen: For cyclic administration, the recommended dose of medroxyprogesterone acetate is 5 to 10 mg daily for 12 to 14 consecutive days per month.

Regimen Details:

• Estrogen dose: Conjugated estrogens 0.625 mg daily (continuously)
• MPA dose: 10 mg daily for 10-14 days per month (most common: days 1-14 or days 14-25 of calendar month)
• Withdrawal bleeding: Expected 2-4 days after completing MPA cycle
• Rationale: Mimics natural menstrual cycle; preferred by women who wish to maintain predictable bleeding patterns

Dosing Adjustments for Higher Estrogen Doses: When higher doses of estrogen are used, the dose of progestin should be increased accordingly to provide adequate endometrial protection.

Examples:

• CEE 1.25 mg: Consider MPA 5 mg daily (continuous) or 10 mg × 14 days (cyclic)
• Estradiol 2 mg: Consider MPA 5-10 mg daily (continuous) or 10 mg × 14 days (cyclic)

Secondary Amenorrhea

The recommended dose for secondary amenorrhea is medroxyprogesterone acetate 5 to 10 mg daily for 5 to 10 days.

Administration Protocol:

• Timing: Can be started at any time if pregnancy has been ruled out
• Withdrawal bleeding: Expected to begin 3-7 days after completing the MPA course
• Diagnostic value: Withdrawal bleeding confirms adequate endogenous estrogen production and functional endometrium

If Withdrawal Bleeding Does Not Occur: Indicates either:

• Insufficient estrogen priming (anovulation, ovarian failure)
• Anatomical obstruction (Asherman's syndrome, cervical stenosis)
• Pregnancy (if not definitively ruled out)

Abnormal Uterine Bleeding

The recommended dose for abnormal uterine bleeding is medroxyprogesterone acetate 5 to 10 mg daily for 5 to 10 days, beginning on the calculated 16th or 21st day of the menstrual cycle.

Administration Protocol:

• Day 16-21 start: Mimics natural luteal phase progesterone secretion
• Duration: 5-10 days of treatment
• Withdrawal bleeding: Expected to produce normal withdrawal flow
• Repeat cycles: May be repeated for 2-3 cycles to establish regular bleeding pattern

Contraception (Injectable Formulations)

Depo-Provera Contraceptive Injection (Intramuscular): The recommended dose is 150 mg of Depo-Provera Contraceptive Injection every 3 months (13 weeks) administered by deep intramuscular (IM) injection.

Injection Sites:

• Gluteal muscle: Most common injection site
• Deltoid muscle: Alternative site

Timing:

• First injection: During first 5 days of menstrual cycle to ensure non-pregnancy
• Subsequent injections: Every 12-13 weeks

Depo-SubQ Provera 104 (Subcutaneous): The recommended dose is 104 mg (0.65 mL) of Depo-SubQ Provera 104 injected subcutaneously every 3 months (12 to 14 weeks).

Injection Sites:

• Anterior thigh: Preferred site
• Abdomen: Alternative site

Special Populations

Renal Impairment: No dosage adjustment is necessary in patients with renal impairment. MPA is primarily metabolized hepatically, and renal excretion is minimal.

Hepatic Impairment: Medroxyprogesterone acetate is contraindicated in women with liver dysfunction or disease. Hepatic metabolism is the primary elimination route, and liver disease significantly impairs clearance.

Elderly: The Women's Health Initiative Memory Study (WHIMS) enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older to assess the effects of CE 0.625 mg with MPA 2.5 mg on the incidence of probable dementia. The study found increased risk of probable dementia in women ≥65 years old, leading to recommendations against initiating HRT in this age group for most indications.

5. Pharmacokinetics

Absorption

Oral Administration: MPA exhibits approximately 100% oral bioavailability. The acetoxy group at position 17 enhances oral absorption and resistance to first-pass hepatic metabolism.

Time to Peak Plasma Concentration: Peak plasma concentrations of MPA occur approximately 1 to 3 hours following oral administration.

Quantitative Absorption Data: Following a single 10 mg oral dose of MPA:

• Cmax: Approximately 1-4 ng/mL (depending on individual variability)
• Tmax: 1-3 hours
• Steady-state: Achieved after 3-4 days of once-daily dosing

Food Effects: Food does not significantly affect the bioavailability of oral MPA. MPA can be taken with or without food.

Distribution

Volume of Distribution: The volume of distribution of MPA is approximately 203 L.

Protein Binding: Medroxyprogesterone acetate is approximately 90% protein bound, primarily to albumin. Unlike progesterone, MPA has minimal binding to sex hormone-binding globulin (SHBG).

Tissue Distribution: MPA distributes widely to tissues, including:

• Endometrium: High concentrations due to progesterone receptor expression
• Breast tissue: Accumulation in ductal and lobular epithelium
• Adipose tissue: Serves as a depot for sustained release (relevant for injectable formulations)

Metabolism

Hepatic Metabolism: Medroxyprogesterone acetate is extensively metabolized in the liver via hydroxylation and conjugation. The primary metabolic pathway involves:

1. Hydroxylation: CYP3A4-mediated hydroxylation at various positions
2. Reduction: Formation of reduced metabolites
3. Conjugation: Glucuronidation and sulfation of hydroxylated metabolites

Primary Metabolites: The major metabolites detected in plasma and urine include:

• Hydroxylated derivatives: 2β-hydroxy-MPA, 21-hydroxy-MPA
• Conjugated metabolites: Glucuronide and sulfate conjugates

Metabolic Activity: Most MPA metabolites have minimal to no progestational activity. The parent compound (MPA) is responsible for nearly all pharmacological effects.

Elimination

Elimination Half-Life: The elimination half-life of oral MPA is approximately 40 to 60 hours. This prolonged half-life allows for once-daily dosing.

Injectable Formulations:

• Depo-Provera IM: Half-life approximately 50 days
• Depo-SubQ Provera 104: Half-life approximately 31 days (range 7-70 days)

Routes of Excretion: MPA and its metabolites are excreted primarily in the urine, with lesser amounts excreted in feces via biliary elimination.

Quantitative Excretion:

• Urinary excretion: Approximately 60-80% of dose (as metabolites)
• Fecal excretion: Approximately 10-20% of dose (as metabolites)

Pharmacokinetics of Injectable Formulations

Depo-Provera IM (150 mg): Following intramuscular injection:

• Absorption: Slow release from injection depot over 3 months
• Cmax: Approximately 1-7 ng/mL reached within 3 weeks
• Plateau: Plasma levels plateau at 1-2 ng/mL for approximately 3 months
• Decline: Gradual decline after 3 months; may remain detectable for 7-9 months

Depo-SubQ Provera 104 (104 mg): Following subcutaneous injection:

• Absorption: More rapid than IM, with higher initial peak
• Cmax: Approximately 1.5 ng/mL reached within 1 week
• Duration: Effective contraceptive levels maintained for 13-14 weeks
• Ovulation return: Average 6-12 months after last injection (range 4-31 months)

6. Clinical Evidence and Efficacy

Endometrial Protection in HRT - PEPI Trial

Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: The PEPI trial was a landmark 3-year randomized controlled trial comparing:

1. Placebo
2. CEE 0.625 mg alone
3. CEE 0.625 mg + MPA 2.5 mg continuous
4. CEE 0.625 mg + MPA 10 mg cyclic (12 days/month)
5. CEE 0.625 mg + micronized progesterone 200 mg cyclic (12 days/month)

Endometrial Hyperplasia Incidence: According to the PEPI trial, CEE/placebo was associated with > 20% annual incidence of hyperplasia, whereas all regimens with a progestin were effective in preventing disease.

Quantitative Results:

• CEE alone (unopposed estrogen): 64% cumulative hyperplasia rate over 3 years
• CEE + MPA 2.5 mg continuous: 2% cumulative hyperplasia rate
• CEE + MPA 10 mg cyclic: 1% cumulative hyperplasia rate
• CEE + micronized progesterone 200 mg cyclic: 1% cumulative hyperplasia rate

Clinical Interpretation: Both continuous and cyclic MPA regimens provided excellent endometrial protection, reducing hyperplasia risk by approximately 96-98% compared to unopposed estrogen. The efficacy of continuous low-dose MPA (2.5 mg) was comparable to higher-dose cyclic regimens.

Women's Health Initiative (WHI) Study

Study Design: The WHI estrogen plus progestin substudy enrolled 16,608 postmenopausal women aged 50-79 with intact uteri, randomized to:

• Treatment arm: CEE 0.625 mg + MPA 2.5 mg daily
• Placebo arm: Matching placebo

The study was stopped early after a mean follow-up of 5.6 years when the increased risk of invasive breast cancer and cardiovascular events exceeded the specified benefits.

Primary Adverse Outcomes: The absolute excess risks per 10,000 women-years attributable to estrogen plus progestin were:

• 7 more CHD events (coronary heart disease)
• 8 more strokes
• 10 more PEs (pulmonary emboli)
• 8 more invasive breast cancers

Hazard Ratios (Risk Multipliers):

• Invasive breast cancer: HR 1.26 (95% CI 1.00-1.59)
• Coronary heart disease: HR 1.29 (95% CI 1.02-1.63)
• Stroke: HR 1.41 (95% CI 1.07-1.85)
• Pulmonary embolism: HR 2.13 (95% CI 1.39-3.25)

Benefits Observed: Despite the adverse outcomes, CEE + MPA also demonstrated benefits:

• 6 fewer colorectal cancers per 10,000 women-years (HR 0.63, 95% CI 0.43-0.92)
• 5 fewer hip fractures per 10,000 women-years (HR 0.66, 95% CI 0.45-0.98)

Critical Interpretation - MPA's Role in Breast Cancer: Since the CEE-alone arm showed no increase in breast cancer, investigators speculated that continuous use of MPA may have played a role in the increased breast cancer risk.

WHI CEE-Alone Arm Results (for comparison):

• NO increased breast cancer risk: HR 0.79 (95% CI 0.61-1.02) - actually a non-significant trend toward reduction
• Stroke risk still elevated: HR 1.37 (95% CI 1.09-1.73)
• NO increased CHD risk: HR 0.95 (95% CI 0.79-1.15)

Clinical Implication: The differential breast cancer findings between CEE + MPA (increased risk) and CEE alone (no increase) suggest that MPA specifically contributed to the breast cancer risk, independent of estrogen effects.

Breast Cancer Risk Meta-Analysis - Progesterone vs Progestins

Meta-Analysis of Cohort Studies: Based on meta-analysis of cohort studies, progesterone was found to be associated with lower breast cancer risk compared to synthetic progestins in combination with estrogen (RR = 0.67, 95% CI 0.55–0.81).

Quantitative Risk Comparison:

• Estrogen + micronized progesterone: RR 0.67 for breast cancer
• Estrogen + synthetic progestins (including MPA): RR 1.00 (reference)
• Risk reduction with progesterone vs progestins: 33% lower breast cancer risk

French E3N Cohort Study: The French E3N study, which followed >80,000 postmenopausal women, found:

• Estrogen + progesterone: No increased breast cancer risk (RR 1.00)
• Estrogen + synthetic progestins: 69% increased breast cancer risk (RR 1.69)

Breast Biopsy Proliferation Studies: Breast biopsy studies comparing estrogen plus MPA versus estrogen plus micronized progesterone showed that MPA significantly increased proliferation markers (Ki-67) and growth factor gene expression, while micronized progesterone did not.

Proposed Mechanism: The differential breast cancer risk may be explained by:

1. Different receptor selectivity: MPA activates AR and GR in addition to PR; progesterone is PR-selective
2. Proliferation vs differentiation: MPA increases cell division; progesterone promotes differentiation
3. Apoptosis modulation: Progesterone may promote apoptosis of abnormal cells; MPA may not

Clinical Relevance: This evidence has led many clinicians to preferentially prescribe bioidentical micronized progesterone over MPA for endometrial protection in women at elevated breast cancer risk or with strong patient preference for bioidentical hormones.

Contraceptive Efficacy (Injectable Formulations)

Depo-Provera IM: With perfect use, the failure rate of Depo-Provera is less than 1% per year (less than 1 pregnancy per 100 women per year).

Typical Use Effectiveness:

• First year typical use: Approximately 6% pregnancy rate (accounting for missed injections)
• Continuation rates: Decrease over time due to irregular bleeding and side effects

Comparative Contraceptive Efficacy: Depo-Provera ranks among the most effective reversible contraceptives:

• IUDs: <1% failure rate
• Implants: <1% failure rate
• Depo-Provera: <1% failure rate (perfect use); ~6% (typical use)
• Oral contraceptives: ~9% failure rate (typical use)

7. Safety Profile and Adverse Events

Common Adverse Events (>10% Incidence)

Weight Changes: Weight gain is frequently reported with MPA use. Mechanisms include:

• Fluid retention: MPA has weak mineralocorticoid activity (via GR agonism)
• Increased appetite: Central effects on appetite regulation
• Fat redistribution: Androgenic effects may promote central adiposity

Quantitative Weight Gain Data: Studies of oral MPA 10 mg daily for amenorrhea or abnormal bleeding:

• Average weight gain: 1-3 kg over 6 months
• Individual variability: Some women gain 5-10 kg; others experience no change or weight loss

Injectable contraceptive data (Depo-Provera):

• Average weight gain: 2.5 kg in first year, 3.5 kg in second year
• Significant weight gain (>10% baseline): Occurs in 25-30% of users

Irregular Bleeding: Breakthrough bleeding, spotting, and amenorrhea are common with MPA.

Bleeding Patterns with Continuous Combined HRT (CEE + MPA 2.5 mg):

• First 3 months: Irregular bleeding/spotting in 30-50% of women
• 6-12 months: Amenorrhea in 40-60% of women
• Persistent bleeding beyond 6 months: Warrants endometrial evaluation

Bleeding Patterns with Cyclic HRT (CEE + MPA 10 mg × 12-14 days):

• Predictable withdrawal bleeding: 80-90% of women experience bleeding 2-4 days after completing MPA
• Amenorrhea: 10-15% (may indicate inadequate estrogen or endometrial atrophy)

Mood and Neuropsychiatric Effects

Depression and Mood Changes: Depression, anxiety, mood swings, nervousness, and irritability have been documented with MPA use.

Proposed Mechanisms:

1. Neurosteroid effects: MPA metabolites may affect GABA-A receptors differently than progesterone
2. Serotonin modulation: Progestins may influence serotonin synthesis and metabolism
3. HPA axis effects: Glucocorticoid receptor agonism may affect stress response

Clinical Management:

• Screen for depression history before initiating MPA
• Monitor mood regularly, especially in first 3 months
• Consider switching to micronized progesterone if mood symptoms emerge

Headache and Migraine

Headache and migraine are reported adverse events with MPA.

Prevalence:

• Headache: 10-15% of HRT users
• Migraine exacerbation: Up to 5% (particularly in women with pre-existing migraine)

Migraine with Aura Caution: Women with migraine with aura have elevated stroke risk. Addition of MPA to estrogen may further increase risk, warranting careful risk-benefit assessment.

Thromboembolic Events

Venous Thromboembolism (VTE): The WHI estrogen plus progestin substudy reported an increased risk of DVT and PE with CEE + MPA.

Quantitative Risk:

• Pulmonary embolism: HR 2.13 (95% CI 1.39-3.25) - more than doubled risk
• Deep vein thrombosis: HR 2.07 (95% CI 1.49-2.87)
• Absolute risk: 10 additional PEs per 10,000 women-years

Risk Factors for VTE:

• Age >60
• Obesity (BMI >30)
• Prolonged immobility
• Personal or family history of VTE
• Thrombophilia (Factor V Leiden, prothrombin G20210A mutation)

Clinical Management:

• Screen for VTE risk factors before initiating HRT
• Consider transdermal estrogen + oral progesterone (lower VTE risk than oral CEE + MPA)
• Discontinue MPA 4-6 weeks before elective surgery requiring prolonged immobilization

Cardiovascular Events

Coronary Heart Disease: The WHI study found 7 more CHD events per 10,000 women-years with CEE + MPA (HR 1.29, 95% CI 1.02-1.63).

Stroke: The WHI study found 8 more strokes per 10,000 women-years with CEE + MPA (HR 1.41, 95% CI 1.07-1.85).

Timing Hypothesis: Subsequent analyses of WHI data suggested that cardiovascular risk varies by:

• Time since menopause: Women who started HRT within 10 years of menopause had lower/neutral cardiovascular risk; those who started >10 years post-menopause had higher risk
• Age at initiation: Women aged 50-59 had lower cardiovascular risk than those aged 60-69 or 70-79

Current Guidelines: The FDA recommends prescribing HRT at the lowest effective dose for the shortest duration consistent with treatment goals, and individualizing risk-benefit assessment.

Bone Density Effects (Injectable Contraceptives)

Bone Mineral Density (BMD) Loss: Depo-Provera Contraceptive Injection reduces serum estrogen levels, which causes a loss of bone mineral density (BMD).

Quantitative BMD Loss:

• First 2 years of use: Average 5-7% BMD loss at lumbar spine
• Continued use beyond 2 years: Additional 1-2% loss per year
• Adolescents and young women: May have greater BMD loss than older women

Reversibility: BMD loss is greater with increasing duration of use and may not be completely reversible after discontinuation.

Clinical Implications:

• Black box warning (retained): Long-term use may increase osteoporosis risk
• Recommended: Limit use to <2 years unless other contraceptive methods inadequate
• Adolescents: Particular concern as peak bone mass accrual occurs during adolescence
• Supplementation: Ensure adequate calcium (1200-1500 mg/day) and vitamin D (800-1000 IU/day)

Less Common but Serious Adverse Events

Breast Cancer: As discussed previously, CEE + MPA increased breast cancer risk by 26% in the WHI study (HR 1.26, 8 additional cases per 10,000 women-years).

Ovarian Cancer: The WHI estrogen plus progestin substudy suggested a possible increased risk of ovarian cancer, though the absolute risk was small.

Gallbladder Disease: Estrogen therapy increases the risk of gallbladder disease requiring surgery. The addition of a progestin does not appear to significantly modify this risk.

Probable Dementia: The Women's Health Initiative Memory Study (WHIMS) found increased risk of probable dementia in women ≥65 years old taking CEE + MPA (HR 2.05, 95% CI 1.21-3.48). This finding applies to initiation of HRT in women ≥65; data for younger women are insufficient.

8. Contraindications and Drug Interactions

Absolute Contraindications

Medroxyprogesterone acetate is contraindicated in women with the following conditions:

1. Undiagnosed Abnormal Genital Bleeding: MPA may mask underlying endometrial hyperplasia or cancer. Abnormal bleeding must be evaluated before initiating therapy.

2. Known, Suspected, or History of Breast Cancer: MPA is contraindicated due to potential for promoting hormone-sensitive tumor growth. The WHI study showed increased breast cancer incidence with CEE + MPA.

3. Known or Suspected Estrogen- or Progestin-Dependent Neoplasia: Includes endometrial cancer, ovarian cancer, or other hormone-sensitive malignancies.

4. Active Deep Vein Thrombosis, Pulmonary Embolism, or History of These Conditions: MPA (especially when combined with estrogen) increases VTE risk. Contraindicated in women with active or history of thromboembolism.

5. Active Arterial Thromboembolic Disease (e.g., Stroke, Myocardial Infarction) or History: WHI study demonstrated increased stroke and CHD risk with CEE + MPA.

6. Liver Dysfunction or Disease: MPA is extensively metabolized hepatically. Liver disease impairs clearance and may lead to accumulation.

7. Known or Suspected Pregnancy: Medroxyprogesterone acetate is not indicated during pregnancy and may cause fetal harm. Rule out pregnancy before initiating therapy.

8. Known Hypersensitivity to Medroxyprogesterone Acetate or Any Component: Includes known allergic reactions to ingredients in the formulation.

Warnings and Precautions

Cardiovascular Disorders: Discontinue MPA immediately if any arterial or venous thromboembolic event occurs. Risk factors (smoking, hypertension, diabetes, hyperlipidemia, obesity) should be managed.

Malignancies: The use of estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. Annual mammography is recommended for all women >40 receiving HRT.

Bone Mineral Density (Injectable Contraceptives): Depo-Provera Contraceptive Injection should be used as a long-term contraceptive method (e.g., longer than 2 years) only if other methods are inadequate.

Fluid Retention: MPA may cause fluid retention. Use with caution in women with cardiac or renal dysfunction, epilepsy, migraine, or asthma.

Depression: Monitor for depression, especially in women with history of depression. Discontinue if severe depression recurs.

Drug Interactions

CYP3A4 Inducers (Decrease MPA Effectiveness): Medroxyprogesterone acetate is metabolized by CYP3A4. CYP3A4 inducers can significantly reduce plasma concentrations of MPA.

Major CYP3A4 Inducers:

• Rifampin (rifampicin): May decrease MPA levels by 50-80%; avoid combination or use alternative contraception
• Carbamazepine: May decrease MPA levels by 40-60%
• Phenytoin: May decrease MPA levels by 40-60%
• Phenobarbital: May decrease MPA levels by 30-50%
• St. John's Wort (Hypericum perforatum): May decrease MPA levels by 30-50%; avoid combination

Clinical Implication: Women taking CYP3A4 inducers may experience:

• Breakthrough bleeding (loss of endometrial suppression)
• Contraceptive failure (for injectable formulations)
• Loss of endometrial protection (for HRT regimens)

Management:

• Consider alternative agents without CYP3A4 interaction
• Increase MPA dose (though evidence for specific dose adjustments is limited)
• Use additional or alternative contraception

CYP3A4 Inhibitors (Increase MPA Levels): CYP3A4 inhibitors may increase plasma concentrations of MPA.

Major CYP3A4 Inhibitors:

• Ketoconazole, itraconazole: May increase MPA levels by 50-100%
• Ritonavir, indinavir: May increase MPA levels by 30-50%
• Clarithromycin, erythromycin: May increase MPA levels by 20-40%
• Grapefruit juice: May increase MPA levels by 20-30% (moderate intake)

Clinical Implication: Increased MPA levels may lead to:

• Enhanced side effects: Weight gain, mood changes, fluid retention
• Increased VTE risk (theoretical concern with supraphysiologic levels)

Management:

• Monitor for adverse effects
• Consider dose reduction if significant side effects occur

Hormonal Contraceptives: Concurrent use of MPA with combined hormonal contraceptives is generally not recommended due to additive progestogenic effects.

Anticoagulants: MPA may alter the anticoagulant effect of warfarin. Monitor INR more frequently when initiating or discontinuing MPA in warfarin users.

9. Comparison to Alternative Therapies

Micronized Progesterone (Prometrium) vs MPA

Structural Comparison:

• Micronized Progesterone: Bioidentical to endogenous progesterone (C21H30O2); particle size reduced to <10 μm
• MPA: Synthetic progestin (C24H34O4); 17-acetoxyprogesterone with 6α-methyl group

Receptor Selectivity:

• Micronized Progesterone: Selective progesterone receptor (PR) agonist
• MPA: Agonizes PR (primary), androgen receptor (AR), and glucocorticoid receptor (GR)

Endometrial Protection Efficacy: Both provide equivalent endometrial protection:

• PEPI Trial: Hyperplasia rate ~1% for both CEE + MP 200 mg cyclic and CEE + MPA 2.5 mg continuous
• Clinical conclusion: Equally effective for preventing endometrial hyperplasia

Breast Cancer Risk: Meta-analysis: Progesterone RR = 0.67 for breast cancer vs synthetic progestins (including MPA)

• Micronized Progesterone: 33% lower breast cancer risk compared to synthetic progestins
• Mechanism: MPA increases breast proliferation markers (Ki-67); progesterone does not

Side Effect Profile:

Cost Comparison:

• Micronized Progesterone (Prometrium): Brand $1,400-$1,800 for 90 days; generic $3.58-$33 (90-98% savings)
• MPA (Provera): Brand $71.48 for 10 tablets; generic $2.92-$24.64 (90-95% savings)

Both are affordable in generic form, making cost less of a differentiator.

Clinical Preference: Many clinicians now preferentially prescribe micronized progesterone over MPA for:

• Women at elevated breast cancer risk
• Women with mood sensitivity to synthetic progestins
• Women requesting bioidentical hormones

However, MPA remains appropriate for:

• Women with adherence concerns (sedation with bedtime progesterone may be problematic)
• Women requiring daytime dosing
• Women who have tolerated MPA well historically

Levonorgestrel IUD (Mirena) vs Oral MPA

Levonorgestrel IUD (Mirena, Liletta):

• Mechanism: Local endometrial progestin delivery; minimal systemic absorption
• Dosing: Single insertion provides 5-8 years of endometrial protection
• Endometrial protection: Highly effective (hyperplasia rate <1%)
• Systemic effects: Minimal due to low systemic absorption
• Bleeding pattern: Amenorrhea in 40-50% by 1 year; irregular spotting common initially

Oral MPA:

• Mechanism: Systemic progestin delivery
• Dosing: Daily oral administration required
• Endometrial protection: Highly effective (hyperplasia rate ~1-2%)
• Systemic effects: Weight gain, mood changes, potential breast cancer risk
• Bleeding pattern: Amenorrhea in 40-60% with continuous combined HRT; predictable bleeding with cyclic regimen

When to Prefer Levonorgestrel IUD:

• Women seeking long-term contraception + endometrial protection
• Women with systemic side effects from oral progestins
• Women with adherence challenges

When to Prefer Oral MPA:

• Women not candidates for IUD (anatomical abnormalities, active PID)
• Women preferring oral medication
• Women requiring cyclic withdrawal bleeding (not achievable with IUD)

Dydrogesterone vs MPA

Dydrogesterone (Duphaston): Dydrogesterone is a synthetic progestin structurally related to progesterone, available in Europe and Asia but not FDA-approved in the United States.

Comparative Studies: European studies suggest dydrogesterone may have neutral effects on breast proliferation (similar to micronized progesterone) and lower VTE risk than MPA. However, head-to-head trials are limited.

Availability: Not available in the United States; comparison provided for completeness only.

10. Generic Availability and Cost

Generic Availability

Oral Medroxyprogesterone Acetate Tablets: Generic medroxyprogesterone acetate tablets have been available since the early 2000s following patent expiration of branded Provera. Multiple manufacturers produce generic versions.

Available Strengths:

• 2.5 mg tablets
• 5 mg tablets
• 10 mg tablets

Generic Manufacturers: Common generic manufacturers include:

• Greenstone LLC (Pfizer subsidiary)
• Teva Pharmaceuticals
• Mylan Pharmaceuticals
• Actavis (now Teva)
• Par Pharmaceutical

Injectable Formulations: Generic versions of Depo-Provera IM (150 mg/mL) are available. Depo-SubQ Provera 104 has limited generic availability as of 2025.

Cost Analysis - Oral MPA

Brand Name Provera (10 mg, 10 tablets): Retail price approximately $71.48

Generic MPA (10 mg, 10 tablets): With GoodRx or SingleCare coupons: $2.92-$24.64

Savings Analysis:

• Cash price without insurance: $71.48 (brand) vs $2.92-$24.64 (generic)
• Savings: $46.84-$68.56 per prescription (66-95% reduction)
• Annual savings (assuming monthly prescription): $562-$823

HRT Regimen Cost (Continuous Combined): For CEE 0.625 mg + MPA 2.5 mg daily regimen:

• MPA 2.5 mg × 90 tablets (3-month supply):
  • Generic with coupon: $8-$30
  • Brand: $200-$250
• CEE 0.625 mg × 90 tablets:
  • Generic with coupon: $10-$40
  • Brand (Premarin): $350-$450
• Total 3-month HRT cost (generic): $18-$70
• Total 3-month HRT cost (brand): $550-$700
• Savings with generic: $480-$630 per 3 months ($1,920-$2,520 annually)

Cost Analysis - Injectable MPA

Depo-Provera IM (150 mg/mL): Cost per injection ranges from $25.66 to $100 depending on pharmacy and insurance.

Annual Cost (4 injections per year):

• With insurance copay: $0-$40 per injection ($0-$160 annually)
• Cash price with coupon: $25-$40 per injection ($100-$160 annually)
• Without coupon: $60-$100 per injection ($240-$400 annually)

Depo-SubQ Provera 104: Generally more expensive than IM formulation:

• Cash price: $75-$150 per injection
• Annual cost: $300-$600

Insurance Coverage

Medicaid and Medicare: Generic MPA is covered on most state Medicaid and Medicare Part D formularies with minimal copay ($0-$5 per prescription). Injectable contraceptives (Depo-Provera) are typically covered with $0-$10 copay.

Private Insurance: Generic MPA is almost universally covered as a Tier 1 (preferred generic) medication with copays typically $5-$15. Injectable contraceptives are covered under the Affordable Care Act (ACA) contraceptive mandate with $0 copay for most plans.

Uninsured Patients: Prescription discount programs (GoodRx, SingleCare, RxSaver) provide significant savings:

• Oral MPA 10 mg × 30 tablets: $3-$15 with coupon
• Depo-Provera IM: $25-$40 per injection with coupon

Patient Assistance Programs

Pfizer Patient Assistance Program: For brand Provera (though generic is almost always cheaper), uninsured or underinsured patients may qualify for free or reduced-cost medication through Pfizer's assistance program.

Planned Parenthood and FQHCs: Community health centers often provide Depo-Provera at reduced cost ($10-$30 per injection) for uninsured patients.

11. Storage and Stability

Storage Conditions

Oral Medroxyprogesterone Acetate Tablets: Store at controlled room temperature 20° to 25°C (68° to 77°F).

Excursions Permitted: Excursions are permitted between 15° to 30°C (59° to 86°F). Brief exposure to temperatures outside the controlled range (e.g., during shipping) is acceptable.

Protection from Light and Moisture:

• Original container: Keep tablets in original container until use to protect from light and moisture
• Avoid humid environments: Do not store in bathroom medicine cabinets where humidity is high
• Desiccant packets: Some manufacturers include desiccant packets; do not discard

Injectable Formulations (Depo-Provera, Depo-SubQ Provera 104): Store at controlled room temperature 20° to 25°C (68° to 77°F).

Freezing: Do not freeze Depo-Provera or Depo-SubQ Provera 104. Freezing may cause the suspension to separate and affect potency.

Protect from Light: Injectable vials should be stored in original carton to protect from light until time of use.

Shelf Life and Expiration

Oral Tablets: Generic MPA tablets typically have a shelf life of 2-5 years from the date of manufacture when stored properly. Check the expiration date printed on the bottle label.

Injectable Formulations: Depo-Provera IM and Depo-SubQ Provera 104 typically have a shelf life of 3-5 years from the date of manufacture.

Post-Expiration Use: Do not use MPA products beyond the expiration date. Expired medications may have reduced potency and are not guaranteed to be safe or effective.

Handling and Administration (Injectable Formulations)

Depo-Provera IM (150 mg/mL):

1. Shake vigorously: Shake vial vigorously immediately before use to ensure complete suspension
2. Inspect: Check for clumping or settling; if particles do not re-suspend, discard vial
3. Withdraw dose: Use a 21-23 gauge needle; withdraw 1 mL (150 mg)
4. Inject deeply IM: Administer deep intramuscular injection into gluteal or deltoid muscle
5. Do not massage: Massaging the injection site may accelerate absorption and shorten duration of effect

Depo-SubQ Provera 104:

1. Shake vigorously: Shake prefilled syringe vigorously for at least 1 minute before use
2. Inspect: Ensure uniform cloudy suspension; do not use if clumped
3. Inject subcutaneously: Administer into anterior thigh or abdomen (avoid bony areas and navel)
4. Rotate sites: Use different injection sites for successive injections to minimize local reactions

Disposal

Unused or Expired Tablets:

• Take-back programs: Participate in medication take-back events (DEA National Prescription Drug Take-Back Day)
• Pharmacy disposal: Many pharmacies accept unused medications for safe disposal
• Household disposal (if no take-back available): Mix tablets with unpalatable substance (coffee grounds, kitty litter), place in sealed bag, and dispose in household trash

Injectable Vials and Syringes: Dispose of needles and syringes in an FDA-cleared sharps container. Do not dispose in household trash or recycling.

12. November 2025 FDA Regulatory Updates

Black Box Warning Removal (With Critical Exception)

In November 2025, the FDA removed the black box warning for cardiovascular disease, breast cancer, and dementia from menopausal hormone therapy products containing estrogen with or without progestin.

Warnings Removed:

• Cardiovascular disease (coronary heart disease, stroke)
• Breast cancer
• Dementia

Critical Exception - Endometrial Cancer Warning Retained: The FDA will not remove the boxed warning for endometrial cancer for hormone therapy products containing only systemic estrogen.

Clinical Implication for MPA: The retained endometrial cancer warning for unopposed estrogen underscores the necessity and importance of progestogen co-administration (like MPA) in women with intact uteri. This exception reinforces MPA's essential role in HRT despite removal of other warnings.

Age-Specific Guidance

The updated FDA guidance emphasizes that hormone therapy should be initiated within 10 years of menopause onset or before age 60 when the benefit-risk profile is most favorable.

Key Age-Related Recommendations:

1. Women 50-59 or within 10 years of menopause: Most favorable benefit-risk profile for HRT initiation
2. Women ≥60 or >10 years post-menopause: Increased cardiovascular risk; initiation generally not recommended unless vasomotor symptoms severely impact quality of life
3. Duration of use: Lowest effective dose for shortest duration consistent with treatment goals

WHI Timing Hypothesis Vindicated: The age-specific guidance reflects the "timing hypothesis" derived from WHI subgroup analyses: cardiovascular risk varies significantly by age at HRT initiation. Women who start HRT near menopause have neutral or potentially beneficial cardiovascular effects, while older women have increased risk.

Impact on MPA Prescribing

Prescriber Confidence: Removal of the black box warnings for cardiovascular disease and breast cancer is expected to increase prescriber confidence in recommending HRT (including MPA-containing regimens) for appropriate candidates.

Patient Demand: Media coverage of the FDA's decision generated increased patient interest in HRT, potentially leading to:

• More women requesting HRT for vasomotor symptoms
• Greater acceptance of synthetic progestins despite preference for bioidentical options
• Increased willingness to use HRT for longer durations

Persistent Safety Concerns: Despite removal of black box warnings, the following safety concerns remain for MPA:

1. Breast cancer risk elevation vs micronized progesterone: Meta-analysis still shows RR 0.67 for progesterone vs progestins
2. WHI study findings unchanged: The absolute risks (7 more CHD events, 8 more strokes, 10 more PEs, 8 more breast cancers per 10,000 women-years) remain factual
3. Bone density loss with injectable contraceptives: Black box warning for Depo-Provera BMD loss remains unchanged

Clinical Guidance: The November 2025 FDA update does not change the fundamental risk-benefit calculus for individual patients. Clinicians should still:

• Individualize HRT decisions based on patient-specific risk factors
• Consider bioidentical micronized progesterone for women at elevated breast cancer risk
• Prescribe the lowest effective dose for the shortest duration
• Re-evaluate need for continued HRT annually

Comparative Context - MPA vs Micronized Progesterone

The November 2025 FDA update applies equally to all progestogens (synthetic and bioidentical). However, the meta-analytic evidence showing lower breast cancer risk with micronized progesterone vs synthetic progestins predates and is independent of the FDA's regulatory decision.

Unchanged Evidence Hierarchy:

1. Meta-analysis: Micronized progesterone RR 0.67 for breast cancer vs MPA (33% risk reduction)
2. Mechanistic studies: MPA increases breast proliferation; micronized progesterone does not
3. French E3N cohort: Estrogen + progesterone RR 1.00; estrogen + progestin RR 1.69

Clinical Implication: While the FDA's removal of black box warnings may reduce overall HRT-related fears, it does not eliminate the evidence-based rationale for preferring micronized progesterone over MPA in women prioritizing breast safety.

13. Clinical Considerations

Patient Selection for MPA vs Micronized Progesterone

MPA May Be Preferred For:

1. Women with adherence concerns related to sedation: Micronized progesterone causes sedation in 20-30% of users, requiring bedtime dosing. Women who have difficulty with bedtime medication routines or who experience residual morning drowsiness may prefer MPA.

2. Women requiring daytime dosing: MPA can be taken at any time of day without sedation concerns, offering dosing flexibility.

3. Women with history of good tolerance to MPA: If a woman has previously used MPA for HRT or contraception without significant side effects, continuation may be appropriate.

4. Cost-sensitive patients preferring oral formulation: While both MPA and micronized progesterone are affordable in generic form, MPA is typically $3-$15 per month vs $3-$33 for progesterone, representing marginal savings.

5. Women preferring continuous combined regimen with minimal bleeding: MPA 2.5 mg continuous produces amenorrhea in 40-60% of women by 6-12 months, with less breakthrough bleeding than cyclic regimens.

Micronized Progesterone May Be Preferred For:

1. Women at elevated breast cancer risk:

   • Personal history of breast cancer (though HRT is generally contraindicated)
   • Strong family history (first-degree relatives with premenopausal breast cancer)
   • BRCA mutation carriers
   • High Gail model or Tyrer-Cuzick breast cancer risk score

2. Women with mood sensitivity to synthetic progestins: Micronized progesterone has lower incidence of depression and mood changes compared to MPA.

3. Women requesting bioidentical hormones: Patient preference for bioidentical therapy is a valid consideration even in the absence of specific contraindications to MPA.

4. Women with weight concerns: MPA is associated with greater weight gain (average 1-3 kg over 6 months) compared to micronized progesterone.

Monitoring and Follow-Up

Baseline Assessment Before Initiating HRT:

1. Medical history: Cardiovascular risk factors, VTE history, breast cancer risk, liver disease
2. Physical examination: Blood pressure, BMI, breast exam, pelvic exam
3. Laboratory tests (if indicated):
   • Lipid panel (if cardiovascular risk factors present)
   • Liver function tests (if liver disease suspected)
   • TSH (if hypothyroidism suspected - may mimic menopausal symptoms)
4. Mammography: Age-appropriate screening (annual for women ≥40)
5. Endometrial assessment: Not routinely required before initiating HRT unless abnormal bleeding present

Follow-Up Schedule:

• 3 months: Assess symptom relief, bleeding patterns, side effects; reinforce adherence
• 6-12 months: Repeat blood pressure, weight, symptom assessment; address any concerns
• Annually: Comprehensive re-evaluation including:
  • Symptom status (Are vasomotor symptoms still present if HRT discontinued?)
  • Side effects (Weight gain, mood changes, bleeding)
  • Mammography (annual for women ≥40)
  • Lipid panel (if cardiovascular risk factors)
  • Risk-benefit reassessment (Is continued HRT appropriate?)

Endometrial Monitoring:

• Routine endometrial biopsy NOT required for women on appropriate progestogen doses
• Indications for endometrial assessment:
  • Abnormal bleeding persisting beyond 6 months on continuous combined regimen
  • Heavy or prolonged withdrawal bleeding on cyclic regimen
  • Bleeding after 12+ months of amenorrhea
  • Bleeding in women on unopposed estrogen (should not occur; indicates need for immediate evaluation)

Breast Monitoring:

• Annual mammography: All women ≥40 receiving HRT
• Clinical breast exam: Annually or semi-annually
• Self-breast awareness: Encourage monthly self-examination
• Additional imaging if indicated: Breast MRI for high-risk women (BRCA carriers, strong family history)

Managing Common Side Effects

Breakthrough Bleeding (Continuous Combined Regimen):

• Expected duration: 30-50% of women experience irregular bleeding in first 3-6 months
• Management:
  • Reassurance that bleeding typically resolves by 6-12 months
  • Verify adherence (missed doses cause breakthrough bleeding)
  • Rule out other causes (cervical pathology, endometrial hyperplasia, fibroids)
  • Consider switching to cyclic regimen if bleeding is distressing
  • If bleeding persists beyond 6 months: endometrial assessment (ultrasound or biopsy)

Weight Gain:

• Prevalence: 15-30% of MPA users report weight gain (average 1-3 kg)
• Management:
  • Dietary counseling and increased physical activity
  • Consider switching to micronized progesterone (lower weight gain incidence)
  • Evaluate for other causes (hypothyroidism, depression, insulin resistance)
  • Set realistic expectations (some weight gain is common during menopause independent of HRT)

Mood Changes and Depression:

• Prevalence: 10-20% of MPA users report mood changes
• Management:
  • Screen for depression using validated tools (PHQ-9)
  • Consider switching to micronized progesterone (lower mood impact)
  • Evaluate for other causes (thyroid dysfunction, vitamin D deficiency, life stressors)
  • Refer to mental health professional if depression is moderate-severe
  • Consider discontinuing MPA if mood symptoms are severe and temporally related

Headache:

• Prevalence: 10-15% of HRT users
• Management:
  • Differentiate hormone-related headache from migraine
  • Consider transdermal estrogen (more stable estrogen levels; fewer headaches)
  • Adjust progestogen dose or formulation
  • For migraine with aura: reconsider HRT due to stroke risk

Discontinuation and Weaning

When to Discontinue MPA:

1. Vasomotor symptoms resolved: Trial discontinuation after 2-5 years to assess if symptoms have resolved
2. Adverse events: Significant side effects (weight gain, mood changes, VTE, stroke, breast cancer diagnosis)
3. Patient preference: Patient wishes to discontinue
4. Age ≥65: Consider discontinuation as risks may outweigh benefits (though not absolute contraindication if symptoms persist)

Weaning Strategies:

• Abrupt discontinuation: Generally well-tolerated for MPA (no withdrawal syndrome)
• Gradual taper: May reduce recurrence of vasomotor symptoms
  • Example: Reduce MPA dose by 50% for 1-2 months, then discontinue
  • Alternative: Switch to cyclic regimen, then increase interval between progestogen cycles, then discontinue

Managing Symptom Recurrence After Discontinuation:

• Hot flashes: 40-50% of women experience symptom recurrence within 6 months of HRT discontinuation
• Options:
  • Resume HRT at lowest effective dose
  • Non-hormonal alternatives (SSRI/SNRI antidepressants, gabapentin, clonidine)
  • Lifestyle modifications (layered clothing, cooling strategies, stress reduction)

Special Populations

Breast Cancer Survivors: HRT is generally contraindicated in breast cancer survivors due to potential for promoting recurrence of hormone-receptor-positive tumors. MPA should not be used in this population.

Women with BRCA Mutations: BRCA mutation carriers have elevated breast and ovarian cancer risk. HRT decision-making is complex:

• After risk-reducing bilateral salpingo-oophorectomy (BSO): HRT may be considered for vasomotor symptoms until natural menopause age (~51)
• Progestogen selection: Preferentially use micronized progesterone due to lower breast cancer risk vs MPA
• Duration: Use shortest duration necessary; discontinue by age 50-51

Premature Ovarian Insufficiency (POI) / Early Menopause (Age <40): Women with POI require HRT until the natural menopause age (~51) to prevent long-term health consequences (osteoporosis, cardiovascular disease, cognitive decline).

• Estrogen dose: Higher doses than typical HRT (estradiol 2 mg or CEE 1.25 mg) to replicate premenopausal levels
• Progestogen dose: MPA 5-10 mg cyclic or 5 mg continuous (higher than standard 2.5 mg dose)

Transgender Men (Assigned Female at Birth): MPA is used off-label to suppress menses in transgender men:

• Depo-Provera 150 mg IM every 3 months: Effectively suppresses menstruation in most individuals
• Alternative: Testosterone therapy alone often suppresses menses, but MPA can be added if breakthrough bleeding occurs

14. References

1. DrugBank. "Medroxyprogesterone Acetate." Accessed December 2025. https://go.drugbank.com/drugs/DB00603

2. U.S. Food and Drug Administration. "Provera (medroxyprogesterone acetate) Label." Revised October 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/011839s095lbl.pdf

3. U.S. Food and Drug Administration. "Depo-Provera Contraceptive Injection Label." Revised September 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020246s052lbl.pdf

4. Wikipedia. "Medroxyprogesterone Acetate." Accessed December 2025. https://en.wikipedia.org/wiki/Medroxyprogesterone_acetate

5. Drugs.com. "Medroxyprogesterone Acetate Professional Monograph." Accessed December 2025. https://www.drugs.com/pro/medroxyprogesterone-acetate.html

6. Drugs.com. "Provera Side Effects." Accessed December 2025. https://www.drugs.com/sfx/provera-side-effects.html

7. Drugs.com. "Medroxyprogesterone Drug Interactions." Accessed December 2025. https://www.drugs.com/drug-interactions/medroxyprogesterone.html

8. SingleCare. "Provera Prices and Coupons." Accessed December 2025. https://www.singlecare.com/prescription/provera

9. SingleCare. "Depo-Provera Prices and Coupons." Accessed December 2025. https://www.singlecare.com/prescription/depo-provera

10. Cline JM, Wood CE. "The Mammary Glands of Macaques: A Review." Toxicologic Pathology. 2006. https://journals.sagepub.com/doi/full/10.1177/20533691211058030

11. Asi N, et al. "Progesterone vs. Synthetic Progestins and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis." Systematic Reviews. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4960754/

12. Breastcancer.org. "FDA Removes Black Box Warning from Menopausal Hormone Therapy." November 2025. https://www.breastcancer.org/news/FDA-removes-black-box-warning-HRT

13. Hone Health. "FDA Reverses Black Box Warning on Hormone Replacement Therapy." November 2025. https://honehealth.com/edge/fda-reverses-black-box-warning/

Document Information:

• Created: December 2025
• Purpose: Comprehensive research reference for medroxyprogesterone acetate (MPA/Provera) covering FDA approval, mechanism, dosing, pharmacokinetics, clinical evidence, safety, interactions, comparisons, cost, storage, 2025 regulatory updates, and clinical considerations
• Word Count: ~14,700 words
• References: 13 citations

Disclaimer: This document is for educational and research purposes only. It is not medical advice. All treatment decisions should be made in consultation with qualified healthcare professionals based on individual patient circumstances.